XSHE
000919
Market cap669mUSD
Feb 24, Last price
7.58CNY
1Q
5.42%
Jan 2017
-43.98%
Name
Jinling Pharmaceutical Co.
Chart & Performance
P/E
116.66
P/S
1.44
EPS
0.06
Div Yield, %
1.34%
Shrs. gr., 5y
3.29%
Rev. gr., 5y
5.30%
Revenues
3.28b
+17.79%
Net income
40m
-59.45%
CFO
154m
-2.98%
Dividend
Jul 08, 20250.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China. The company offers Mailuoning injection for the treatment of thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and sequelae, multiple arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; and lentinan injection for treatment of malignant tumors. It also provides medical health care services. Jinling Pharmaceutical Company Limited is based in Nanjing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||